VEGFA and wet macular degeneration: In 2004, bevacizumab, a humanized full-length immunoglobulin G against VEGF, was approved by the US Federal Drug Administration for the management of colon cancer.[4] Bevacizumab is now being used as an “off-label” intravitreal agent for wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusions globally.[5] Intravitreal injections of ranibizumab and aflibercept are both approved for wet-type AMD and macular edema due to retinal vascular disorders.